Recursion is a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation.

View our most recent corporate materials.

Recent News
Nov 8, 2022
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results

Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficile...

Nov 2, 2022
Recursion to Participate in Upcoming Investor Conferences

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:...

Oct 25, 2022
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the...

Stock Info
NASDAQRXRX